Showing results (151-160 of 165) with videos related to
Sort By:
Pageof 17
Blood|April 14, 2026
Diagnosis-to-Treatment Interval Is Associated With Outcomes in Follicular Lymphoma Treated with ImmunochemotherapyProkop Vodička, Tarec C El-Galaly, Vit Prochazka, et al.The Lancet. Haematology|July 21, 2024
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN studyWilliam G Wierda, Nirav N Shah, Chan Y Cheah, et al.The New England Journal of Medicine|July 5, 2023
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic LeukemiaAnthony R Mato, Jennifer A Woyach, Jennifer R Brown, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2023
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell LymphomaMichael L Wang, Wojciech Jurczak, Pier Luigi Zinzani, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2026
High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter AnalysisMatthew R Wilson, Katharine L Lewis, Amy A Kirkwood, et al.NPJ Vaccines|November 1, 2024
Safety, efficacy and immunogenicity of aerosolized Ad5-nCoV COVID-19 vaccine in a non-inferiority randomized controlled trialChun K Chew, Ruijie Wang, Sunita Bavanandan, et al.Haematologica|October 4, 2024
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trialNirav N Shah, Michael Wang, Lindsey E Roeker, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2013
Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patientsRoberto N Miranda, Tariq N Aladily, H Miles Prince, et al.The Lancet. Haematology|May 2, 2026
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trialM Lia Palomba, Manish R Patel, Toby A Eyre, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2024
International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin LymphomaMichael Sargent Binkley, Jamie E Flerlage, Kerry J Savage, et al.Pageof 17